Literature DB >> 10836998

Frequent mutations of the beta-catenin gene in mouse colon tumors induced by azoxymethane.

M Takahashi1, S Nakatsugi, T Sugimura, K Wakabayashi.   

Abstract

The beta-catenin gene is frequently mutated at codons 33, 41 and 45 of the glycogen synthase kinase-3beta phosphorylation motif in human colon cancers in patients without APC mutations. Frequent mutations at codons 32 and 34, as well as 33 and 41, have been detected in rat colon tumors induced by azoxymethane (AOM), with the second G of CTGGA sequences being considered as a mutational hot-spot. In the present study, exon 3 of the beta-catenin gene in mouse colon tumors induced by AOM was amplified by PCR and mutations were detected by the single strand conformation polymorphism method, restriction enzyme fragment length polymorphism and direct sequencing. All 10 colon tumors tested were found to have beta-catenin mutations, four in codon 34, three in codon 33, two in codon 41 and one in codon 37, nine being G:C-->A:T transitions. However, no mutations were found in codon 32 of the mouse beta-catenin gene. On immmunostaining, beta-catenin was observed in the cytoplasm and nucleus of the tumor cells. The cytoplasmic staining was homogeneous, while both homogeneous and heterogeneous patterns were noted for the nuclei. Highly frequent mutations of the beta-catenin gene in AOM-induced mouse colon tumors suggest that consequent alterations in the stability and localization of the protein may play an important role in this colon carcinogenesis model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10836998

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  53 in total

1.  Sex modulates intestinal transformation by the tumor-suppressor GCC.

Authors:  Peng Li; Stephanie Schulz; Giovanni M Pitari; Scott A Waldman
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

2.  Sex modulates intestinal transformation by the tumor-suppressor GCC.

Authors:  Peng Li; Stephanie Schulz; Giovanni M Pitari; Scott A Waldman
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

3.  Genetic and Chemical Models of Colorectal Cancer in Mice.

Authors:  Mandayam O Nandan; Vincent W Yang
Journal:  Curr Colorectal Cancer Rep       Date:  2010-03-10

4.  Protein kinase C isozymes as therapeutic targets for treatment of human cancers.

Authors:  Alan P Fields; Nicole R Murray
Journal:  Adv Enzyme Regul       Date:  2008-03-18

5.  Colon carcinogenesis in wild type and immune compromised mice after treatment with azoxymethane, and azoxymethane with dextran sodium sulfate.

Authors:  Ryan D Whetstone; Uwe A Wittel; Nicole M Michels; James M Gulizia; Barry Gold
Journal:  Mol Carcinog       Date:  2015-07-08       Impact factor: 4.784

6.  The myc 3' wnt-responsive element suppresses colonic tumorigenesis.

Authors:  Wesley M Konsavage; Gregory S Yochum
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

7.  PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1.

Authors:  Marybeth A Pysz; Olga V Leontieva; Nicholas W Bateman; Joshua M Uronis; Kathryn J Curry; David W Threadgill; Klaus-Peter Janssen; Sylvie Robine; Anna Velcich; Leonard H Augenlicht; Adrian R Black; Jennifer D Black
Journal:  Exp Cell Res       Date:  2009-02-14       Impact factor: 3.905

Review 8.  Murine models of colorectal cancer.

Authors:  Joshua M Uronis; David W Threadgill
Journal:  Mamm Genome       Date:  2009-05-15       Impact factor: 2.957

9.  PUMA suppresses intestinal tumorigenesis in mice.

Authors:  Wei Qiu; Eleanor B Carson-Walter; Shih Fan Kuan; Lin Zhang; Jian Yu
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

10.  Nuclear expression of β-catenin promotes RB stability and resistance to TNF-induced apoptosis in colon cancer cells.

Authors:  Jinbo Han; Rossana C Soletti; Anil Sadarangani; Priya Sridevi; Michael E Ramirez; Lars Eckmann; Helena L Borges; Jean Y J Wang
Journal:  Mol Cancer Res       Date:  2013-01-21       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.